After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

Keytruda plus Lenvima demonstrates durable 5-year survival benefit versus chemotherapy for patients with advanced endometrial carcinoma following one prior platinum-based regimen ...

Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to ...

Merck (MRK), known as MSD outside of the United States and Canada, announced results demonstrating KEYTRUDA plus Padcev reduced the risk of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results ...

Merck (MRK) and Eisai (ESAIY) announced long-term follow-up data continued to show durable benefit of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine ...

Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer ...

The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...

Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, ...

KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial ...

Merck leads U.S. pharma in 2025, but faces Keytruda patent loss by 2028. Click for my look at MRK stock ahead of its upcoming ...